Anti-CDH6 antibody drug conjugates
US-9982045-B2 · May 29, 2018 · US
Anti-CDH6 antibody drug conjugates
US10238748B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10238748-B2 |
| Application number | US-201515502478-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 7, 2015 |
| Priority date | Aug 12, 2014 |
| Publication date | Mar 26, 2019 |
| Grant date | Mar 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an CDH6 positive cancer in a patient in need thereof, comprising administering to said patient an antibody drug conjugate of the formula: or a pharmaceutical composition thereof; wherein; n is an integer from 1 to 10 and said Ab is an antibody or antigen binding fragment thereof comprising: (i) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:224, (b) a LCDR2 of SEQ ID NO:225, (c) a LCDR3 of SEQ ID NO:226; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO: 227, (e) a HCDR2 of SEQ ID NO: 228, and (f) a HCDR3 of SEQ ID NO:229; (ii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:210, (b) a LCDR2 of SEQ ID NO:211, (c) a LCDR3 of SEQ ID NO:212; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:213, (e) a HCDR2 of SEQ ID NO: 214, and (f) a HCDR3 of SEQ ID NO:215; (iii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:266, (b) a LCDR2 of SEQ ID NO:267, (c) a LCDR3 of SEQ ID NO:268; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO: 269, (e) a HCDR2 of SEQ ID NO:270, and (f) a HCDR3 of SEQ ID NO: 271; (iv) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:308, (b) a LCDR2 of SEQ ID NO:309, (c) a LCDR3 of SEQ ID NO:310; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:311, (e) a HCDR2 of SEQ ID NO:312, and (f) a HCDR3 of SEQ ID NO:313; (v) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:14, (b) a LCDR2 of SEQ ID NO:15, (c) a LCDR3 of SEQ ID NO:16; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:17, (e) a HCDR2 of SEQ ID NO:18, and (f) a HCDR3 of SEQ ID NO:19; (vi) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:28, (b) a LCDR2 of SEQ ID NO:29, (c) a LCDR3 of SEQ ID NO:30; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:31, (e) a HCDR2 of SEQ ID NO:32, and (f) a HCDR3 of SEQ ID NO:33; (vii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:42, (b) a LCDR2 of SEQ ID NO:43, (c) a LCDR3 of SEQ ID NO:44; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:45, (e) a HCDR2 of SEQ ID NO:46, and (f) a HCDR3 of SEQ ID NO:47; (viii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:56, (b) a LCDR2 of SEQ ID NO:57, (c) a LCDR3 of SEQ ID NO:58; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:59, (e) a HCDR2of SEQ ID NO:60, and (f) a HCDR3 of SEQ ID NO:61; (ix) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:70, (b) a LCDR2 of SEQ ID NO:71, (c) a LCDR3 of SEQ ID NO:72; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:73, (e) a HCDR2 of SEQ ID NO:74, and (f) a HCDR3 of SEQ ID NO:75; (x) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:84, (b) a LCDR2 of SEQ ID NO:85, (c) a LCDR3 of SEQ ID NO:86; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:87, (e) a HCDR2 of SEQ ID NO: 88, and (f) a HCDR3 of SEQ ID NO: 89; (xi) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:98, (b) a LCDR2 of SEQ ID NO:99, (c) a LCDR3 of SEQ ID NO:100; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:101, (e) a HCDR2 of SEQ ID NO:102, and (f) a HCDR3 of SEQ ID NO:103; (xii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:112, (b) a LCDR2 of SEQ ID NO:113, (c) a LCDR3 of SEQ ID NO:114; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:115, (e) a HCDR2 of SEQ ID NO:116, and (f) a HCDR3 of SEQ ID NO:117; (xiii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:126, (b) a LCDR2 of SEQ ID NO:127, (c) a LCDR3 of SEQ ID NO:128; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:129, (e) a HCDR2 of SEQ ID NO:130, and (f) a HCDR3 of SEQ ID NO:131; (xiv) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:140, (b) a LCDR2 of SEQ ID NO:141, (c) a LCDR3 of SEQ ID NO:142; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:143, (e) a HCDR2 of SEQ ID NO:144, and (f) a HCDR3 of SEQ ID NO:145; (xv) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:154, (b) a LCDR2 of SEQ ID NO:155, (c) a LCDR3 of SEQ ID NO:156; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:157, (e) a HCDR2 of SEQ ID NO:158, and (f) a HCDR3 of SEQ ID NO:159; (xvi) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:168, (b) a LCDR2 of SEQ ID NO:169, (c) a LCDR3 of SEQ ID NO:170; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:171, (e) a HCDR2 of SEQ ID NO:172, and (f) a HCDR3 of SEQ ID NO:173; (xvii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:182, (b) a LCDR2 of SEQ ID NO:183, (c) a LCDR3 of SEQ ID NO:184; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:185, (e) a HCDR2 of SEQ ID NO:86, and (f) a HCDR3 of SEQ ID NO:187; (xviii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:196, (b) a LCDR2 of SEQ ID NO:197, (c) a LCDR3 of SEQ ID NO:198; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:199, (e) a HCDR2 of SEQ ID NO:200, and (f) a HCDR3 of SEQ ID NO:201; (xix) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:238, (b) a LCDR2 of SEQ ID NO:239, (c) a LCDR3 of SEQ ID NO:240; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:241, (e) a HCDR2 of SEQ ID NO:242, and (f) a HCDR3 of SEQ ID NO:243; (xx) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:252, (b) a LCDR2 of SEQ ID NO:253, (c) a LCDR3 of SEQ ID NO:254; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:255, (e) a HCDR2 of SEQ ID NO:256, and (f) a HCDR3 of SEQ ID NO:257; (xxi) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:280, (b) a LCDR2 of SEQ ID NO:281, (c) a LCDR3 of SEQ ID NO:282; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:283, (e) a HCDR2 of SEQ ID NO:284, and (f) a HCDR3 of SEQ ID NO:285; (xxii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:294, (b) a LCDR2 of SEQ ID NO:295, (c) a LCDR3 of SEQ ID NO:296; and a heavy chain variable region that comprises: (d) a HCDR1 of SEQ ID NO:297, (e) a HCDR2 of SEQ ID NO:298, and (f) a HCDR3 of SEQ ID NO:299; or (xxiii) a light chain variable region that comprises (a) a LCDR1 (CDR-Complementarity Determining Region) of SEQ ID NO:322, (b) a LCDR2 of SEQ ID NO:323, (c) a LCDR3 of
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
involving compounds localised on the membrane of tumour or cancer cells · CPC title
the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10238748B2 cover?
- The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
- Who is the assignee on this patent?
- Bialucha Carl Uli, Collins Scott, Duerr Clemens, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).